They're both anti-IL-1β agents, but failure of anakinra in adult-onset Still's Disease doesn't mean canakinumab might not work (and work quickly) - see row 7-10 below. Anyone else have that experience? Corrado @Giacomo97811458, San Raffaele Hosp, Milan #ACR19 ABST1245 @RheumNow https://t.co/2qQK08apnT

Relapsing polychondritis (RP) has always struck me as a condition with highly variable implications - and this cluster analysis from the @NIH_NIAMS prospective cohort agrees. There's RP, and then there's RP! @maferradastrong @petercgrayson et al #ACR19 ABST1719 @RheumNow https://t.co/mbfbTxwc6U

RCT Tildrakizumab (IL23i) in Psoriatic Arthritis Beat PLBO for ACR20 (NNT~4), ACR50 (NNT~4), and pt global (NNT~3 for 50% improvement) Very well tolerated (NNH>50, any adverse event) Exciting new tx! Need comparison RCT vs TNF/IL17i @RheumNow #acrbest #ACR19 Abst#1821 https://t.co/QFQEA8L3sY

#ACR19 @rheumnow ABS 1237 OLT1177, oral NLRP3 inflammasome inhibitor- a potential drug for Rx of gout flares: ⬇️ systemic inflamm by ⬇️ WBC count & circulating IL-1β& IL-6 in all3 doses (2000mg, 1000mg or 300mg). ⬇️ ex vivo IL-1β & IL-6 production by cultured PBMCs days 3, 7& 14

#ACR19 @rheumnow abs1353 Observational SMART-RA trial concludes smart phone app based RA management improves DAS28 (p < 0.05), ESR (p≤0.05), CRP (p≤0.05) and HAQ-DI (p≤0.5) after 1y of use, suggesting smart phone technology improves quality of life & disease control in RA https://t.co/rERu2oF2VT

Abstr#1759: 64 pts randomized to either MTX 10mg or PBO. Evolution of pain b/w 2 groups no different. Function no different. Dose too low? PBO effect? Structural evolution modified by MTX. Is that our goal? #ACR19 @RheumNow #OA #osteoarthritis

#Rheumatology is the best field in medicine! #RheumatologyMeme #ACR19 @ACRheum https://t.co/SmxjmTbV0j

PATCH study: HCQ 400mg started by wk 10 gestation significantly reduces the recurrence of CHB below the historical rate of 18% to 7.4%. #ACR19 @RheumNow

IFX detected in stool a/w higher CRP and active bowel disease. An inflamed bowel can change the pharmacodynamics of some of the therapies we use. Low albumin may indicate leaky gut. #ACR19 @RheumNow #IBD #AS #ankylosingspondylitis https://t.co/1BTU0guOC1

Choosing the right medication matters, but choosing the wrong medication also matters - Dr. Edward Behrens #ACR19 @RheumNow

Higher risk patients – Antimalarial Retinal Toxicity - Concomitant tamoxifen (increase risk 5-fold) - GFR <50 cc/min - Dose >5 mg/kg #ACR19 @RheumNow

Urate lowering therapy indications for #Gout: - Tophi - Frequent flares ( ≥ 2/yr) - Chronic kidney disease - Hx of renal stones Will these change in the 2019 guidelines? #ACR19 @RheumNow

🤳My first ever selfie video series -- I ask the experts for some twitter advice! Come tag along with me :) #ACR19 @RheumNow @ACRheum @UTHealth

Retrospective review of 236 RA pts and 166 pts w/other systemic diseases who received Shingrix: no significant increase risk in disease flare or vaccine-related AEs. Abstr#1804 #ACR19 #whyivaccinate @RheumNow @LCalabreseDO @BetsyKirch

Abstr#1802 - nice study from @CleClinicMD confirming low clinical value of annual quantiferon screening for LTBI in the absence of new or ongoing risk factor #ACR2019 @RheumNow @ElaineHusniMD #cleclinicrheum